Mark A. Velleca - 15 Jun 2021 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
15 Jun 2021
Net transactions value
-$647,321
Form type
4
Filing time
17 Jun 2021, 16:05:43 UTC
Previous filing
25 May 2021
Next filing
15 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 15 Jun 2021 Direct
transaction GTHX Common Stock Sale $223,909 -10,000 -14% $22.39* 61,000 15 Jun 2021 Direct F1, F2
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 16 Jun 2021 Direct
transaction GTHX Common Stock Sale $217,384 -10,000 -14% $21.74* 61,000 16 Jun 2021 Direct F1, F3
transaction GTHX Common Stock Options Exercise $3,900 +10,000 +16% $0.3900* 71,000 17 Jun 2021 Direct
transaction GTHX Common Stock Sale $217,728 -10,000 -14% $21.77* 61,000 17 Jun 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -3.5% $0.000000 277,286 15 Jun 2021 Common Stock 10,000 $0.3900 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -3.6% $0.000000 267,286 16 Jun 2021 Common Stock 10,000 $0.3900 Direct F5
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -10,000 -3.7% $0.000000 257,286 17 Jun 2021 Common Stock 10,000 $0.3900 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $22.10 and a high of $22.64. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 The price represents the weighted average price with a low of $21.55 and a high of $21.87. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
F4 The price represents the weighted average price with a low of $21.44 and a high of $21.92. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
F5 All shares underlying this option have vested.